The company buys in a PI3Kα and mTOR combo.
ApexOnco Front Page
Recent articles
Gilead opting against IDE397 is still good news for Ideaya.
But the Japanese group is focused on biliary tract cancer rather than glioblastoma.
On a cross-trial basis varegacestat beats Ogsiveo.
No fewer than four ADCs with this target start human testing.
The company is set to start a phase 2/3 trial this month.
The group will start a pivotal trial of samuraciclib following promising second-line results.
Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
